FDA Does Away With CBER’s Allergenic Products Advisory Committee

The FDA has opted to terminate CBER’s Allergenic Products Advisory Committee due to the expert group’s relative inactivity over the past few years, shifting its duties over to the Vaccines and Related Biological Products Advisory Committee (VRBPAC).
Source: Drug Industry Daily